**RAPID ALERT**

**DRAP ALERT NO.** Nº I/S/06-23-24

# FALSIFIED PHENOBAR 30MG TABLETS

**Date:** 5th June 2023

## Target Audience:

- Regulatory Field Force.
- Healthcare Professionals - Physicians, Pharmacists, and Nurses.
- General Public.

## Problem Statement:

Drug Inspectorate field force including various Provincial Inspector of Drugs took samples of Phenobar 30mg Tablets from the market and ask purported manufacturer i-e M/s Star Laboratories (Pvt.) Lt. Lahore, for verification of authenticity/owner ship claim of following batches of their registered product, i-e Tablet Phenobar 30 mg containing Phenobarbitone. Legal manufacturer of this product, tablet Phenobar 30 mg, has disowned these batches of and claimed these batches to be spurious /falsified.

The product detail is as under: -

| **Product Name** | **Batch No.** | **Manufactured by (as stated on the label)** | **Remarks** |
|---|---|---|---|
| Phenobar Tablets 30mg (Phenobarbitone) | **QA019, QA025, QA016.** | M/s Star Laboratories (Pvt) Ltd .Lahore | Registration holder company informed that these batches were not manufactured by them. |

## Risk Statement:

Consequences of use of Spurious/ Falsified Drugs includes but not limited to followings:

- Falsified/Spurious drugs may contain toxic and narcotic/psychotropic ingredients in unacceptable doses which may be life threating.
- These are manufactured under un hygienic condition without the proper inspection and approval, which are highly injurious to human health.
- Poor-quality medicines compromise the treatment of diseases and may intensified the existing condition.

**DRAP, Islamabad** **92 51 9107404** **gsms@dra.gov.pk**

## Action Initiated: -

The Regulatory Field Force has been directed to increase surveillance throughout the supply chain to confiscate these products. All Pharmacists, chemists, and other healthcare professionals working at distributions, pharmacies, healthcare facilities, and other aspects of the supply chain system should **immediately check** the stock, and information related to the supplier of such products should be provided to the Regulatory field force (DRAP, Provincial Health Departments and States) to ensure the removal of this product.

## Advice for Healthcare Professionals: -

DRAP requests increased vigilance at hospitals and within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by this product.

Adverse reactions or quality problems experienced with the use of this product shall be reported to the National Pharmacovigilance Centre(NPC), DRAP using Adverse Event Reporting Form or online through this link. Further information on reporting problems to DRAP is available on this link.

## Advice for Consumers / General public: -

Consumers should not use this product and shall contact their physician or healthcare provider if they have experienced any problem related to taking or using this drug product, and should report the incident to the Drug Regulatory Authority of Pakistan / National Pharmacovigilance Centre.

All therapeutic goods must be obtained from licensed pharmacies and other authorized/licensed retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professionals in case of any doubt.

**Drug Regulatory Authority of Pakistan**
محفوظ، موئثر اور معیاری اشیائے علاج

DRAP, Islamabad | 92 51 9107404 | gsms@dra.gov.pk